Zydus Lifesciences Limited Asset Resilience Ratio
Zydus Lifesciences Limited asset resilience ratio. Zydus Lifesciences Limited (ZYDUSLIFE) has an Asset Resilience Ratio of 9.14% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ZYDUSLIFE defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Zydus Lifesciences Limited (2012–2025)
Asset resilience ratio of Zydus Lifesciences Limited from 2012 to 2025. This chart shows how Zydus Lifesciences Limited's Asset Resilience Ratio has changed over time. Read Zydus Lifesciences Limited balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Zydus Lifesciences Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Zydus Lifesciences Limited total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs42.86 Billion | 9.14% |
| Total Liquid Assets | Rs42.86 Billion | 9.14% |
Asset Resilience Insights
- Limited Liquidity: Zydus Lifesciences Limited maintains only 9.14% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zydus Lifesciences Limited Industry Peers by Asset Resilience Ratio
Compare Zydus Lifesciences Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Zydus Lifesciences Limited Asset Resilience Ratio by Year (2012–2025)
Zydus Lifesciences Limited asset resilience ratio by year from 2012 to 2025. The table below shows the annual Asset Resilience Ratio data for Zydus Lifesciences Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 18.82% | Rs70.01 Billion ≈ $757.17 Million |
Rs372.02 Billion ≈ $4.02 Billion |
+15.52pp |
| 2024-03-31 | 3.30% | Rs9.67 Billion ≈ $104.54 Million |
Rs292.81 Billion ≈ $3.17 Billion |
+0.58pp |
| 2023-03-31 | 2.72% | Rs7.00 Billion ≈ $75.68 Million |
Rs257.56 Billion ≈ $2.79 Billion |
-7.53pp |
| 2022-03-31 | 10.24% | Rs28.47 Billion ≈ $307.89 Million |
Rs277.95 Billion ≈ $3.01 Billion |
+8.31pp |
| 2021-03-31 | 1.93% | Rs4.62 Billion ≈ $49.96 Million |
Rs238.85 Billion ≈ $2.58 Billion |
-0.15pp |
| 2020-03-31 | 2.09% | Rs4.94 Billion ≈ $53.46 Million |
Rs236.87 Billion ≈ $2.56 Billion |
-0.38pp |
| 2019-03-31 | 2.47% | Rs5.80 Billion ≈ $62.69 Million |
Rs234.83 Billion ≈ $2.54 Billion |
-0.17pp |
| 2018-03-31 | 2.64% | Rs4.77 Billion ≈ $51.61 Million |
Rs180.65 Billion ≈ $1.95 Billion |
+2.24pp |
| 2017-03-31 | 0.40% | Rs614.00 Million ≈ $6.64 Million |
Rs152.21 Billion ≈ $1.65 Billion |
-1.92pp |
| 2016-03-31 | 2.33% | Rs2.33 Billion ≈ $25.21 Million |
Rs100.16 Billion ≈ $1.08 Billion |
+0.99pp |
| 2015-03-31 | 1.34% | Rs1.21 Billion ≈ $13.11 Million |
Rs90.47 Billion ≈ $978.41 Million |
+0.53pp |
| 2014-03-31 | 0.81% | Rs644.00 Million ≈ $6.96 Million |
Rs79.86 Billion ≈ $863.71 Million |
-0.46pp |
| 2013-03-31 | 1.27% | Rs933.00 Million ≈ $10.09 Million |
Rs73.72 Billion ≈ $797.28 Million |
+1.22pp |
| 2012-03-31 | 0.05% | Rs30.00 Million ≈ $324.44K |
Rs63.79 Billion ≈ $689.89 Million |
-- |
About Zydus Lifesciences Limited
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, con… Read more